NEWARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that management will participate in four investor conferences in March, including the 31st Annual ROTH Conference in Laguna Niguel, California, the Oppenheimer 29th Annual Healthcare Conference in New York City, the Oppenheimer’s Biotech Summit by the Lake at Northwestern University in Evanston, Illinois, and the ROTH Battle of NASH Thrones Spring Investor Conference in New York City.
|31st Annual ROTH Conference|
|Date:||Monday, March 18|
|Time:||9:30am Pacific Time|
|Format:||Panelist: Why Knowing NASH as a Generalist Can Make You Rich in 2019|
|Time:||12:00pm Pacific Time|
|Oppenheimer 29th Annual Healthcare Conference|
|Date:||Tuesday, March 20|
|Time:||8:35am Eastern Time|
|Oppenheimer’s Biotech Summit by the Lake|
|Date:||Wednesday, March 27|
|Time:||1:00pm Central Time|
|ROTH Battle of NASH Thrones Spring Investor Conference|
|Date:||Thursday, March 28|
|Time:||8:00 am Eastern Time|
|Format:||Panel: 12 Months of Data - 2019 Is the Year for FXR and PPAR Clinical Readouts|
|Time:||4:00pm Eastern Time|
|Format:||Panel: Why MRI May Hold the Key to the Kingdom in Diagnosis and Drug Development|
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay’s lead development candidate, seladelpar, is a potent, selective and orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar (ENHANCE) in patients with PBC. Seladelpar received orphan designation for PBC from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation for PBC from the FDA and Priority Medicine status from the EMA. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar for patients with NASH.
For additional information about CymaBay visit www.cymabay.com.
LifeSci Advisors, LLC